Open Access

Non-steroidal anti-inflammatory drugs and their benefits and harms: the challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported

Arthritis Research & Therapy201517:130

https://doi.org/10.1186/s13075-015-0650-1

Published: 21 May 2015

Abstract

A multitude of reports have delineated the risks of using non-steroidal anti-inflammatory drugs but have not been totally congruent. Meta-analyses of randomized controlled trials sometimes concur regarding gastrointestinal risk and cardiovascular risk but rarely report a balance of these risks for any one drug. Benefits measured in these studies are usually not reported. Observational data sets, supposedly reflective of ‘real world’ patients, do not always agree with the randomized controlled trial reports. Clinicians need assessments measuring the balance of harms and benefits so that better decisions based on their patients’ unique risk factors can be reached.

Van Walsem and colleagues, in a recent article in Arthritis Research & Therapy, performed a network meta-analysis uniquely comparing diclofenac in terms of benefit and concomitant risk with other non-steroidal anti-inflammatory drugs (NSAIDs) as well as with coxibs [1]. Diclofenac at 150 mg/day has better pain relief than celecoxib, naproxen, and ibuprofen, but diclofenac at 100 mg/day has benefits similar to those of the comparators. Furthermore, diclofenac is similar to the coxibs (and maybe worse than etoricoxib) in terms of gastrointestinal (GI) risk and better than that observed with naproxen or ibuprofen treatment; interestingly, in this data set including 146,524 patients from 176 randomized controlled trials (RCTs), there was no difference between therapies regarding cardiovascular (CV) risk.

We are frequently bombarded by new reports which often conflict. These are either observational data sets or yet another meta-analysis of multiple RCTs of varying lengths, with details regarding the risk of using an NSAID. Unfortunately, almost all of these studies present evidence regarding the drug's risk of either a CV event or a GI event and do not compare the balance of risk between these CV or GI events for any one drug in a single report, nor have the same studies assessed efficacy at the same time. The Coxib and Traditional NSAID Trialists’ Collaboration developed a meta-analysis of 280 RCTs of NSAIDs versus placebo (124,513 patients) and 474 trials of one NSAID versus another (229,296 patients), focusing on risk for major CV events (non-fatal myocardial infarction, non-fatal stroke, or CV death), all-cause mortality, heart failure, and upper GI complications (perforation, obstruction, or bleed) [2]. That report is informative compared with earlier data sets since we learn that naproxen might be safer for patients with CV risk but that it is one of the worst NSAIDs in terms of risk for a major GI complication. By providing similar evidence but including data regarding benefit would give far better information for the clinician to choose a drug for any one patient while considering that patient’s unique risk factors.

More evidence was contributed by a US Food and Drug Administration Arthritis Advisory Committee meeting convened to determine whether naproxen was safe in terms of CV risk [3]. There was no agreement that naproxen has been proven to be safe at this time. The only added information was the recognition that the risk for a CV event may be earlier in treatment than previously thought. Thus, this earlier CV risk mirrors the early risk for GI ulcer damage reported to be present within seven days of systemic therapy, even in normal human volunteers endoscoped for that purpose [4].

For clinicians, it must be difficult to consider this conflicting evidence as it has evolved. Achieving adequate pain relief is an important treatment goal. There is evidence that chronic pain, particularly severe pain such as pain resulting in inactivity, is associated with increased all-cause mortality [58]. Some well-designed observational studies fail to corroborate increased CV risk with NSAIDs and suggest that long-term treatment with NSAIDs or coxibs is associated with a substantially reduced incidence of CV events and all-cause mortality perhaps linked to increased activity with adequate pain relief [7, 8].

In some studies, NSAIDs and coxibs have lower rates of significant harm than opioids in large matched cohorts [9]. Despite this evidence, some developers of treatment guidelines have chosen to suggest opioids as alternative therapies for patients, implying that opioids would be safer than the NSAIDs [10]. By suggesting opioid therapy as an alternative, these guideline developers have chosen to ignore the ample literature demonstrating serious risks for many patients using opioids. These risks include dysphoria, which can lead to increased patient falls and consequent hip fracture in older patients. A large propensity-matched study reported the incidence of fracture with opioids to be five times higher than that with NSAIDs in older adults, and hospital admission for adverse events and all-cause mortality were also higher with opioids [5, 9]. A meta-analysis of RCTs of NSAID use indicates a 45 % increased risk of a CV event compared with placebo and this translates to a 0.3 % increased absolute risk per year compared with a background risk of about 1 % per year in the at-risk population [5].

A clinician needs clear guidance to be able to choose the right type of therapy for the individual patient. Pain needs to be treated with therapies which provide substantive benefit. For patients with chronic pain, there is a problem of confounding by indication. There is an increased risk for CV events in untreated patients due to decreased physical functioning and consequent increased inactivity. [5]. Balancing the risk of no treatment with the competing potential risks of various therapies is the clinician’s responsibility, and the report by van Walsem and colleagues [1] helps to improve our understanding of exactly what these competing risks may mean for our patients.

Notes

Abbreviations

CV: 

Cardiovascular

GI: 

Gastrointestinal

NSAID: 

Non-steroidal anti-inflammatory drug

RCT: 

Randomized controlled trial

Declarations

Authors’ Affiliations

(1)
SDG LLC, One Mifflin Place

References

  1. van Walsem A, Pandhiz S, Nixon RM, Guyot P, Karabis A, Moore AR. Relative benefit-risk comparing diclofenac to other traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network metaanalysis. Arthritis Res Ther. 2015;17:66.View ArticlePubMed CentralPubMedGoogle Scholar
  2. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.View ArticleGoogle Scholar
  3. US Food and Drug Administration. Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 10–11 February 2014. http://www.fda.gov/AdvisoryCommittees/Calendar/ucm380871.htm. Accessed 25 February 2015.
  4. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998;41:1591–602.View ArticlePubMedGoogle Scholar
  5. Moore RA, Derry S, Simon LS, Emery P. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract. 2014;14:378–95.View ArticlePubMedGoogle Scholar
  6. Sokka T, Pincus T. Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care. BMJ Open. 2011;1, e000070.View ArticlePubMed CentralPubMedGoogle Scholar
  7. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.View ArticlePubMed CentralPubMedGoogle Scholar
  8. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367–72.View ArticlePubMed CentralPubMedGoogle Scholar
  9. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968–76.View ArticlePubMedGoogle Scholar
  10. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–42.View ArticlePubMedGoogle Scholar

Copyright

© Simon; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement